Trevi Therapeutics Advances Clinical Programs and Financial Status
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company, is making noteworthy strides in its clinical programs aimed at treating chronic cough due to idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The recent completion of significant enrollment phases and the anticipated outcomes of these studies signify a promising direction for the company as they continue to address the critical needs of patients.
Key Developments in Clinical Trials
Enrollment and Results Expectations
The company has successfully completed the enrollment of the Phase 2a RIVER trial targeting refractory chronic cough, expecting to release topline results in early 2025. In addition to this, they have achieved 50% enrollment in the Phase 2b CORAL trial that focuses on chronic cough associated with idiopathic pulmonary fibrosis. Sample size re-estimation for this trial is expected by December 2024, with subsequent results anticipated in the first half of 2025, contingent on no further adjustments to the sample size.
Current Financial Position
As of the end of the third quarter, Trevi Therapeutics reported a cash position of $65.5 million, providing a substantial runway into the second half of 2026. This strong cash position is vital as the company navigates through its clinical developments and operational expenses.
Financial Overview and Performance
Research and Development Costs
In the latest financial report, Trevi revealed that research and development (R&D) expenses climbed to $11.2 million during the third quarter of 2024, up from $6.3 million in the same quarter the previous year. This increase reflects intensified clinical development activities in both the Phase 2 trials and the Human Abuse Potential (HAP) study.
General Operating Expenses
General and administrative (G&A) expenses for the third quarter saw a slight rise to $2.9 million compared to $2.7 million in the prior year's period, primarily due to increased stock-based compensation. Overall, the company experienced a net loss of $13.2 million this quarter, compared to a net loss of $7.7 million in the third quarter of 2023.
Strategic Expansion and Leadership Changes
New Leadership Appointment
Further enhancing its strategic vision, Trevi announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer during the third quarter. Dr. Cassella's extensive experience is expected to bolster the company's development efforts as they move forward with crucial clinical trials.
Participating in Upcoming Conferences
Looking ahead, Trevi plans to participate in several significant healthcare conferences. Notable dates include the Stifel 2024 Healthcare Conference and the Piper Sandler 36th Annual Healthcare Conference. These events will serve as platforms for Trevi to engage with investors and industry colleagues, discussing their progress and future directions.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is focused on developing Haduvio™, an investigational therapy designed for the treatment of chronic cough associated with both idiopathic pulmonary fibrosis and refractory chronic cough. Haduvio targets the cough reflex arc, leveraging its unique kappa agonist and mu antagonist properties to potentially lessen the cough reflex and improve patient quality of life. Unfortunately, there are currently no approved therapies addressing chronic cough, which affects a substantial portion of the IPF community, with many patients facing immense challenges due to this condition.
Frequently Asked Questions
What is Trevi Therapeutics, Inc. primarily working on?
Trevi Therapeutics is developing Haduvio™, aimed at treating chronic cough associated with IPF and RCC.
When can we expect results from the RIVER trial?
Topline results from the Phase 2a RIVER trial are expected in the first quarter of 2025.
What was Trevi's cash position at the end of Q3 2024?
Trevi reported a cash position of $65.5 million, sufficient to support operations into the second half of 2026.
Who was appointed as Chief Development Officer?
James V. Cassella, Ph.D. was appointed as Chief Development Officer during the third quarter of 2024.
What conferences will Trevi attend?
Trevi plans to participate in the Stifel 2024 Healthcare Conference and the Piper Sandler 36th Annual Healthcare Conference in the upcoming months.
